PureTech Health (LON:PRTC) Reaches New 12-Month Low – What’s Next?

PureTech Health plc (LON:PRTC)’s stock price reached a new 52-week low during trading on Friday . The stock traded as low as GBX 131.80 ($1.70) and last traded at GBX 136.20 ($1.76), with a volume of 5294853 shares changing hands. The stock had previously closed at GBX 134.80 ($1.74).

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 455 ($5.88) price target on shares of PureTech Health in a report on Monday, December 16th.

PureTech Health Price Performance

The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The company has a market cap of £409.12 million, a PE ratio of -5.59 and a beta of 1.02. The stock has a 50-day simple moving average of GBX 144.22 and a 200 day simple moving average of GBX 153.18.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.